Charles Schwab Investment Management Inc Trevena Inc Transaction History

Charles Schwab Investment Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.2 - $0.5 $77,785 - $194,463	-388,926 Reduced 80.58%	93,743 $39,000
Q1 2022 May 13, 2022	BUY	$0.41 - $0.63 $17,322 - $26,616	42,249 Added 9.59%	482,669 $266,000
Q3 2021 Nov 16, 2021	BUY	$1.11 - $1.7 $45,450 - $69,608	40,946 Added 10.25%	440,420 $542,000
Q2 2021 Aug 16, 2021	BUY	$1.46 - $2.25 $506,148 - $780,023	346,677 Added 656.62%	399,474 $676,000
Q1 2021 May 17, 2021	SELL	$1.77 - $2.93 $36,605 - $60,595	-20,681 Reduced 28.15%	52,797 $95,000
Q3 2020 Nov 13, 2020	BUY	$1.53 - $3.13 $63,675 - $130,264	41,618 Added 130.63%	73,478 $220,000
Q1 2019 May 14, 2019	BUY	$0.51 - $1.88 $16,248 - $59,896	31,860 New	31,860 $50,000
Q3 2018 Nov 13, 2018	SELL	$1.39 - $2.25 $31,313 - $50,688	-22,528 Closed	0 $0
Q2 2018 Aug 08, 2018	SELL	$1.44 - $2.24 $175,440 - $272,908	-121,834 Reduced 84.39%	22,528 $33,000
Q1 2018 May 07, 2018	BUY	$1.51 - $2.06 $77,312 - $105,472	51,200 Added 54.96%	144,362 $237,000
Q4 2017 Jan 17, 2018	SELL	$1.4 - $2.6 $47,840 - $88,847	-34,172 Reduced 26.84%	93,162 $150,000
Q3 2017 Nov 13, 2017	BUY	$2.22 - $2.79 $282,681 - $355,261	127,334	127,334 $325,000

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $273M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.